Cargando...
Cost‐effectiveness and financial risks associated with immune checkpoint inhibitor therapy
The reimbursement of immune checkpoint inhibitors is challenging. Funding these technologies involves the careful balance between awarding innovation and ensuring affordability as increases in drug spending compete directly with other health care and social expenditure. This narrative review examine...
Gardado en:
| Publicado en: | Br J Clin Pharmacol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7444763/ https://ncbi.nlm.nih.gov/pubmed/32358803 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.14337 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|